Background. Sodium glucose cotransporter‐2 (SGLT2) inhibitors have been proven to be
very effective in the management of type II diabetes. These medications can cause adverse …

Results from major clinical trials have shown significant cardiorenal‐protective benefits of
SGLT2 inhibitors in patients with type 2 diabetes (T2DM), leading to increased popularity. A …

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are the most recently approved drug
class for the treatment of type 2 diabetes mellitus (T2D). Although they are largely well …

Introduction Sodium-glucose cotransporter 2 (SGLT2)-inhibitors are new antihyperglycemic
agents that have shown a reduction in cardiovascular events in type 2 diabetes mellitus …

ABSTRACT Background: Type 2 diabetes (T2DM) is becoming more prevalent worldwide
and sodium-glucose co-transporter-2 (SGLT2) inhibitors are being increasingly used in its …

Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat
diabetes. At present, the Food and Drug Administration (FDA) has only approved three …

Objective: Euglycemic diabetic ketoacidosis (DKA) is a known potential complication from
sodium-glucose cotransporter 2 (SGLT2) inhibitor use. We present a unique case …

Interventions: She was treated with intravenous infusions of insulin, isotonic saline, and
sodium bicarbonate as diabetic ketoacidosis treatment. Outcomes: She was in shock with …

SGLT-2 inhibitors have gained importance in recent years because of their cardio-protective
and reno-protective properties in diabetes. SGLT-2 inhibitors, when introduced in diabetic …

Euglycemic diabetic ketoacidosis is a post market warning in patients with type 1 diabetes
and type 2 diabetes treated with SGLT-2 inhibitors. We report a case of a 39-year-old obese …